

A dynamic prognostic model for Polycythemia Vera long-terms outcomes in patients treated with Ruxolitinib after Hydroxyurea failure

PV-RR6 score

Francesca Palandri¹, Alessandra Dedola^{1,2}, Giovanni Caocci³, Elena Rossi^{4,5}, Elena M. Elli⁶, Chiara Sartor^{1,2}, Roberto Latagliata⁷, Novella Pugliese⁸, Erika Morsia⁹, Gianni Binotto¹⁰, Francesco Mendicino¹¹, Alessia Tieghi¹², Giulia Benevolo¹³, Bruno Martino¹⁴, Alessandra D'Addio¹⁵, Mario Tiribelli¹⁶, Daniela Cilloni¹⁷, Monica Crugnola¹⁸, Fabrizio Cavalca⁶, Emilia Scalzulli¹⁹, Francesco Lanza¹⁵, Fabrizio Pane⁸, Giuseppe A. Palumbo²⁰, Florian H. Heidel²¹, Valerio De Stefano^{4,5}, Massimo Breccia^{19*}, Filippo Branzanti^{2*}

†These authors contributed equally to this work

*These authors contributed equally to this work

1. IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy;
2. Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Bologna, Italy;
3. Ematologia, Ospedale Businco, Università degli studi di Cagliari, Cagliari, Italy;
4. Fondazione Policlinico A. Gemelli IRCCS, Rome, Italy;
5. Section of Hematology, Department of Radiological and Hematological Sciences, Catholic University, Rome, Italy;
6. Fondazione IRCCS San Gerardo dei Tintori, Divisione di ematologia e unità trapianto di midollo, Monza, Italy;
7. Hematology Unit, Ospedale Belcolle, Viterbo, Italy;
8. Department of Clinical Medicine and Surgery, Hematology Section, University of Naples "Federico II", Naples, Italy;
9. Hematology Unit, Department of Clinical and Molecular Sciences, DISCLIMO, Università Politecnica delle Marche, Ancona, Italy;
10. Unit of Hematology and Clinical Immunology, University of Padova, Padova, Italy;
11. U.O.C. di Ematologia, Department of Hemato-Oncology, Azienda Ospedaliera Annunziata, Cosenza, Italy;
12. Department of Hematology, Azienda USL - IRCCS di Reggio Emilia, Reggio Emilia, Italy;
13. University Hematology Division, Città della Salute e della Scienza Hospital, Torino, Italy;
14. Division of Hematology, Azienda Ospedaliera 'Bianchi Melacrino Morelli', Reggio Calabria, Italy;
15. Division of Hematology, Onco-hematologic Department, AUSL della Romagna, Ravenna, Italy;
16. Division of Hematology and BMT, Department of Medicine, University of Udine, Udine, Italy;
17. Department of Clinical and Biological Sciences, University of Turin, Turin, Italy;
18. Haematology and BMT Centre, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy;
19. Division of Cellular Biotechnologies and Hematology, University Sapienza, Roma, Italy;
20. Department of Scienze Mediche, Chirurgiche e Tecnologie Avanzate "G.F. Ingrassia", University of Catania, Catania, Italy
21. Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School (MHH), Hannover, Germany

Corresponding Author

Chiara Sartor

IRCCS Azienda Ospedaliero-Universitaria di Bologna


Institute of Hematology "L. and A. Seràgnoli"

Tel +39 051 214 3044


Fax +39 051 636 4037

e-mail: chiara.sartor2@unibo.it


Supplemental Figure 1: Sankey flow diagram for phlebotomies requirement status at baseline, 3, and 6 months of ruxolitinib treatment




Supplemental Figure 2: Sankey flow diagram for leukocytosis (leukocytes count $\geq 10 \times 10^9/L$) status at baseline, 3, and 6 months of ruxolitinib treatment




Supplemental Figure 3: Sankey flow diagram for thrombocytosis (platelet count $\geq 400 \times 10^9/L$) status at baseline, 3, and 6 months of ruxolitinib treatment




Supplemental Figure 4: Sankey flow diagram for splenomegaly status at baseline, 3, and 6 months of ruxolitinib treatment



Supplemental Figure 5: Sankey flow diagram for ruxolitinib dose at treatment start and after 3 and 6 months of treatment



Supplemental Figure 6: Outcomes by Responses at 6 months



Supplemental Figure 6: Kaplan-Meier curves illustrating outcomes based on response type. From left to right: spleen response and complete hematological response. The outcomes shown from top to bottom include Event-Free Survival (EFS), Myelofibrosis-Free Survival (MFS), Overall Survival (OS), and Thrombosis-Free Survival (TFS). SR, Spleen Response; CHR, complete hematological response.